Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study

Abstract

Early administration of melatonin to asphyxiated term neonates is feasible and may ameliorate brain injury.

Melatonin Acts in Synergy with Hypothermia to Reduce Oxygen-Glucose Deprivation-Induced Cell Death in Rat Hippocampus Organotypic Slice Cultures

“…They reported that melatonin augmented a hypothermia-improved cerebral energy metabolism and reduced cell death after perinatal asphyxia, with plasma concentrations of melatonin ranging between 17 and 31 mg/mL (74-134 μM). In agreement, a small randomized controlled pilot study in which melatonin was enterally administered to neonates with HIE undergoing hypothermia showed fewer seizures on follow-up EEG and less white matter abnormalities in the melatonin/hypothermia group [27]. At 6 months, this study also reported improved survival without neurological or developmental abnormalities [27].…”

“…In agreement, a small randomized controlled pilot study in which melatonin was enterally administered to neonates with HIE undergoing hypothermia showed fewer seizures on follow-up EEG and less white matter abnormalities in the melatonin/hypothermia group [27]. At 6 months, this study also reported improved survival without neurological or developmental abnormalities [27]. A clinical trial to study the neuroprotective properties and the appropriate dosage of melatonin for neonates undergoing therapeutic hypothermia after HIE is currently in progress [28].…”

A novel LC–MS/MS assay for the simultaneous determination of melatonin and its two major metabolites, 6-hydroxymelatonin and 6-sulfatoxymelatonin in dog plasma: Application to a pharmacokinetic study

“…Due to its significant biological effect in the regulation of sleep-wake cycle, exogenous MEL is widely used in clinic for the treatment of sleep-related disorders. In recent years, the use of exogenous MEL has been enlarged with the identification of its other potential bioactivities in neuroprotection [3], immunoregulation [4], antioxidation [5,6], anti-tumor [7], and cardioprotection [8].…”

Recent Information on the Pathogenesis and Treatment of Hypoxic-Ischemic Brain Lesions in Newborns

“…На моделях асфик-сии у животных мелатонин показал способность защи-тить мозг как самостоятельно, так в комбинации с гипо-термией [108,109]. Появились и первые клинические данные: рандомизированное контролируемое пилотное исследование в Египте с участием 30 новорожденных с ГИП и 15 здоровых детей показало, что сочетание внутривенного введения мелатонина (в течение первых 5 дней) и терапевтической гипотермии у детей с уме-ренной и тяжелой степенью ГИП было эффективным в снижении окислительного стресса, улучшало состояние белого вещества по данным МРТ, уменьшало судорожную готовность на ЭЭГ и, в конечном счете, приводило к улуч-шению выживаемости с благоприятным исходом в пси-хомоторном развитии в возрасте 6 мес [110]. Показана также эффективность мелатонина для недоношенных детей [111].…”